Industry News
Pharmaceutical Industry News
Trump Demands That Drugmakers Lower Some of Their U.S. Prices by September
The administration has not put forward a clear legal authority to compel drugmakers to reduce their prices.
GSK signed a 12-asset licensing…
GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is nearing the purchase of a large U.S. facility to help mitigate the impact of tariffs. And
The latest move by President…
The latest move by President Donald Trump to try to implement so-called “Most Favored Nation” drug pricing may be more bark than bite, one group of analysts contends.
Merck will reduce its workforce by…
Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey drugmaker told Fierce Pharma. Word of the dismissals comes two days after Merck revealed a sweeping
In what has become a trend among…
In what has become a trend among European drugmakers presenting second-quarter earnings this week, the leadership at France’s Sanofi says it has little to be concerned about after a 15% tariff on European pharmaceutical shipments
A year after debuting the “Rare…
A year after debuting the “Rare Connections” series with a short film about patients’ experiences with neuromyelitis optica spectrum disorder, AstraZeneca’s rare disease unit is turning the cameras on generalized myasthenia gravis.
Applications are now open for a…
Applications are now open for a pilot program swapping out 340B providers' upfront discounts for equivalent post-purchase payments, an approach drugmakers say will reduce duplicate discounts and improve transparency.
The company’s 7% quarterly sales…
The company's 7% quarterly sales growth prompted an updated full-year sales outlook to flat, up from a previously expected slight decline.
On a day when AbbVie revealed…
On a day when AbbVie revealed booming sales of Skyrizi and Rinvoq and another positive adjustment to its 2025 guidance, the company also is reportedly angling to bolster its long-term prospects by way of an
Bristol Myers Squibb had a strong…
Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s expectations. But CEO Chris Boerner still decided to address the company’s recent
The announcement of a 15% tariff…
The announcement of a 15% tariff on pharmaceutical imports to the U.S. from the EU may have not been the ideal backdrop for the busiest week of European pharma earnings this quarter, but CEOs appeared
Moderna is taking its downsizing…
Moderna is taking its downsizing scheme a step further with plans to shrink its global workforce by around 10%. By the end of the year, the company expects to employ “fewer than 5,000 colleagues,” CEO
Evotec has inked a deal to sell…
Evotec has inked a deal to sell its biosimilars manufacturing facility in Toulouse, France to generics giant Sandoz for roughly $300 million. The transaction advances Evotec's plan to forge an "asset-lighter and capital-efficient" model for
The sudden departure of Vinay…
The sudden departure of Vinay Prasad, M.D., from the FDA again threw the cell and gene therapy field into uncertainty. But this time, the unknown is hitting the industry in a different way from when
Eli Lilly has presented phase 3…
Eli Lilly has presented phase 3 results showing its Mounjaro measures up to the company’s GLP-1 Trulicity in reducing cardiovascular risks in patients with Type 2 diabetes and heart disease. While Lilly called it a
The first commercial for Johnson…
The first commercial for Johnson & Johnson and Legend Biotech’s Carvykti focuses on the numbers that make up a multiple myeloma patient’s life, both before and after treatment with the CAR-T therapy.
As Celltrion looks to ward off…
As Celltrion looks to ward off potential import tariffs, the South Korean company’s odds at acquiring a large-scale drug substance plant in the U.S. have gone up considerably.
Following the departure of Vinay…
Following the departure of Vinay Prasad, M.D., former head of the Center for Biologics Evaluation and Research, the FDA has already tapped someone else to temporarily fill his shoes.
The Japanese drugmaker’s quarterly…
The Japanese drugmaker's quarterly revenues took an 8.4% hit with continued Vyvanse-related generic erosion reaching a high and bringing down its U.S. sales.
With a portfolio of 14 potential…
With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ($53